HomeCompareBHBCQ vs ABBV

BHBCQ vs ABBV: Dividend Comparison 2026

BHBCQ yields 200000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BHBCQ wins by $4.875657285131069e+59M in total portfolio value
10 years
BHBCQ
BHBCQ
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full BHBCQ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BHBCQ vs ABBV

📍 BHBCQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBHBCQABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BHBCQ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BHBCQ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BHBCQ
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BHBCQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BHBCQ + ABBV for your $10,000?

BHBCQ: 50%ABBV: 50%
100% ABBV50/50100% BHBCQ
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BHBCQ
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BHBCQ buys
0
ABBV buys
0
No recent congressional trades found for BHBCQ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBHBCQABBV
Forward yield200000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.875657285131069e+59M$102.3K
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.875656971401711e+59M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BHBCQ vs ABBV ($10,000, DRIP)

YearBHBCQ PortfolioBHBCQ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$11,550$430.00+$20000.00MBHBCQ
2$37,383,218,970,104,910$37,383,197,570,093,464.00$13,472$627.96+$37383218970.09MBHBCQ
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$15,906$926.08+$65303942472059152.00MBHBCQ
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$19,071$1,382.55+$1.0661500906030689e+23MBHBCQ
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$23,302$2,095.81+$1.6267227396708296e+29MBHBCQ
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$29,150$3,237.93+$2.319663403067553e+35MBHBCQ
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$37,536$5,121.41+$3.091381823051466e+41MBHBCQ
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$3.850317772522584e+47MBHBCQ
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$4.481844117993459e+53MBHBCQ
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.875657285131069e+59MBHBCQ

BHBCQ vs ABBV: Complete Analysis 2026

BHBCQStock

Beverly Hills Bancorp Inc. is a financial holding company and conducts its banking and lending operations through its primary subsidiary, First Bank of Beverly Hills. The Bank focuses on niche products, including the origination and acquisition of commercial and multi-family real estate loans. The Bank's principal funding sources consist of certificates of deposits generated through independent brokers and its money desk, borrowings from the Federal Home Loan Bank of San Francisco and repurchase agreements with major investment banks. The Bank is a California state-chartered commercial bank and is regulated by the Federal Deposit Insurance Corporation. Beverly Hills Bancorp's common stock is traded on the Nasdaq National Market under the trading symbol "BHBC".

Full BHBCQ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BHBCQ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BHBCQ vs SCHDBHBCQ vs JEPIBHBCQ vs OBHBCQ vs KOBHBCQ vs MAINBHBCQ vs JNJBHBCQ vs MRKBHBCQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.